Over the past decade, improvements in RMS survival rates of more than 70% for patients with localized disease were achieved but new treatment options are still required for patients with metastatic disease or aggressive molecular features such as somatic mutations in MYOD1. The gene discussed is MYOD1; the disease is metastatic neoplasm.